On
Shareholders who have comments and suggestions are asked to contact the Chairman of the Nomination Committee, Magnus Essand with email info@elicera.com
For further information please contact:
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
About the iTANK platform
The iTANK- (immunoTherapies Activated with NAP for efficient Killing) platform is the company's own fully developed commercially available technology platform for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of the CAR T-cell in addition to activating a parallel immune response via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK-platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. More information about iTANK-platform is available here: https://www.elicera.com/technology
About
For more information, please visit www.elicera.com
https://news.cision.com/elicera-therapeutics/r/nomination-committee-for-elicera-therapeutics-appointed,c3661106
https://mb.cision.com/Main/20218/3661106/1648266.pdf
(c) 2022 Cision. All rights reserved., source